Observational studyESC heart failure2026
Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device-a real-world, single-centre, observational study.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Closing the gap between trial and clinical reality in long-term left ventricular assist device use outcomes.ESC heart failure · 2026Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLeft ventricular assist device (LVAD) therapy is an established treatment modality for patients with advanced heart failure with reduced ejection fraction (HFrEF). This study aimed to evaluate the long-term outcomes of patients implanted with a Heartmate 3 LVAD.
methodsWe included 176 patients who were implanted with a HeartMate 3 LVAD at the University Medical Center Groningen (UMCG) between 2016 and 2025. The primary outcome of interest was on device survival. Secondary outcomes were major adverse events (including device dysfunction, major bleeding, device-related infections, ventricular tachycardia, cerebrovascular events and heart failure hospitalizations) stratified according to LVAD treatment strategy.
resultsMean age at implantation was 56 ± 11 years, and 26% were female. The initial device strategy was bridge to transplant (BTT) in 24%, destination therapy (DT) in 34%, and bridge to decision (BTD) in 42%. Overall survival was 87%, 82% and 61% at 1, 2 and 5 years respectively. Kaplan-Meier analysis suggested longer on-device survival in BTT compared with DT patients, although interpretation is limited by differential censoring due to transplantation. Device-related infections and heart failure hospitalizations were the most common major adverse events, occurring 0.29 and 0.18 events per patient-year at risk, respectively. Device dysfunction and cerebrovascular events were rare, with incidence rates of 0.04 and 0.02 events per patient-year at risk, respectively. No LVAD pump thrombosis events were recorded during this time period.
conclusionLong-term survival on HeartMate 3 LVAD support exceeded 60% at 5 years in this single-centre cohort. While adverse events such as device related infections and heart failure hospitalizations continue to pose a substantial clinical challenge, the incidence of thrombotic complications was low, underscoring improvement in clinical outcomes with current generation centrifugal LVAD devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.